Harbin Medisan Pharmaceutical Co Ltd
SZSE:002900
Harbin Medisan Pharmaceutical Co Ltd
SZSE:002900
Price:
12.04
CNY
-0.41%
Market Closed
Market Cap:
¥3.8B
Relative Value
The Relative Value of one
Harbin Medisan Pharmaceutical Co Ltd
stock under the Base Case scenario is
8.76
CNY.
Compared to the current market price of 12.04 CNY,
Harbin Medisan Pharmaceutical Co Ltd
is
Overvalued by 27%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
8.76
CNY
Overvaluation 27%
Multiples Across Competitors
Competitors Multiples
Harbin Medisan Pharmaceutical Co Ltd Competitors
Harbin Medisan Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Harbin Medisan Pharmaceutical Co Ltd
SZSE:002900
|
3.8B CNY | 4.4 | -20 | -21 | -21 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD | 15.2 | 48.1 | 32.4 | 34.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
591.4B USD | 6.3 | 22 | 15.3 | 18.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
292.8B CHF | 4.8 | 31.3 | 13.2 | 15.4 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.2B GBP | 5.5 | 31.7 | 17.5 | 24.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
244.9B CHF | 5.6 | 22.6 | 13.9 | 17.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
307.5B USD | 4.7 | 16.8 | 10.5 | 12.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 3.7 | 11.3 | 8.3 | 9.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.9B USD | 2.5 | 19.8 | 7.4 | 9.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.8B USD | 2.6 | 17.5 | 7.3 | 9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
